JPRN-jRCT2080221447未知3 期
AJH801 Phase III Comparative Clinical Study in individuals with essential hypertension
Ajinomoto Pharmaceuticals Co., Ltd.0 个研究点目标入组 600 人开始时间: 2011年4月27日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •In observation period
- •-140 mmHg < the sitting SBP at trough < 199 mmHg
- •- 90 mmHg < the sitting DBP at trough < 114 mmHg
- •At the end of observation period
- •-150 mmHg < the sitting SBP at trough < 199 mmHg
- •- 95 mmHg < the sitting DBP at trough < 114 mmHg
- •The difference in observation period
- •-The difference between the sitting trough SBP at 2 points in observation period is within 30 mmHg.
- •-The difference between the sitting trough DBP at 2 points in observation period is within 15 mmHg.
排除标准
- •- Females who are pregnant, are breast-feeding, are potentially pregnant, are planning to be pregnant during the study period
- •- Patients with secondary hypertension, or suspected of having secondary hypertension
- •- Significant heart, renal, hepatic diseases or significant cerebrovascular disorder
研究者
相似试验
未知
3 期
Phase III Clinical Study of AJG522 : Studies of safety and efficacy of AJG522 as a colon preparation agent for colonoscopy - Comparative study with MGV-5Patients scheduled for colonoscopyJPRN-jRCT2080221438Ajinomoto Pharmaceuticals Co., Ltd.
未知
3 期
Phase III clinical study of AFT-801 (confirmatory study) Double-blind, placebo-controlled study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsExcessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsJPRN-jRCT2080220352Mitsubishi Tanabe Pharma Alfresa Pharma Corporation
未知
3 期
Phase 3 clinical study of AFT-801(confirmatory study 0305) Double-blind, placebo-controlled study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsExcessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsJPRN-jRCT2080220749Mitsubishi Tanabe Pharma Alfresa Pharma Corporation
未知
2 期
Phase II/III induction study of AJG501 in patients with active ulcerative colitislcerative colitisJPRN-jRCT2080221110Ajinomoto Pharmaceuticals Co., Ltd.
已完成
3 期
Phase III study of AJM300 in patients with active ulcerative colitis (2)Active Ulcerative ColitisJPRN-jRCT2080223867EA Pharma Co., Ltd.198